10:25 AM EDT, 06/24/2024 (MT Newswires) -- Revelation Biosciences' ( REVB ) shares surged 33% in recent trading Monday after the company announced its investigational drug Gemini met the primary endpoint of safety and tolerability of escalating doses in healthy volunteers during a phase 1 study in Australia.

The company is developing Gemini as a potential pretreatment to prevent or reduce the severity of acute kidney injury due to cardiac surgery and to reduce the incidence, duration and severity of post-surgical infection.

The company is "committed to moving rapidly into a Phase 1b study in patients late 2024," Revelation Biosciences ( REVB ) Chief Executive Officer James Rolke said Monday in a statement.

Price: 2.81, Change: +0.70, Percent Change: +33.05